Entinostat was granted FDA breakthrough status for advanced breast cancer in 2013 based on positive efficacy results from the phase II study ENCORE 301 combining entinostat with an aromatase inhibitor (AI), as well as encouraging results from other phase II studies [16, 24–27]. Here, CYP19A1 is linked to breast carcinoma.